BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv4.7.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.mdtechcouncil.com/membership/events
X-WR-CALDESC:Events for 
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241107T080000
DTEND;TZID=America/New_York:20241107T180000
DTSTAMP:20260415T023224
CREATED:20241018T023931Z
LAST-MODIFIED:20241018T023931Z
UID:4848-1730966400-1731002400@www.mdtechcouncil.com
SUMMARY:Advancing Medical Applications of Cancer Nanotechnology
DESCRIPTION:\n\n\nThe Nanotechnology Characterization Laboratory (NCL) has made significant strides in advancing cancer nanotechnology over the past two decades. Established by the National Cancer Institute in 2004 in collaboration with the US Food and Drug Administration and the National Institute of Standards and Technology\, NCL has played a crucial role in bridging the gap between nanotechnology innovations and their clinical applications in oncology. \nTo celebrate two successful decades of NCL’s contributions to advancing the field of cancer nanotechnology\, this symposium brings together NCL scientists\, collaborators\, and researchers applying nanotechnology to improve current treatment strategies and develop innovative therapies\, vaccines\, and diagnostics to combat cancer and the detrimental side-effects of many existing standard of care treatments. \nThe agenda includes presentations across industries\, with collaborators from academia\, government\, and pharma. \nBackground: Who is the Nanotechnology Characterization Laboratory?\nThe Nanotechnology Characterization Laboratory serves as a resource and knowledge base for all cancer researchers—academia\, industry\, and government—to facilitate the development and clinical translation of novel nanotechnologies intended as cancer therapeutics\, vaccines\, and diagnostics. \nNCL’s key contributions to the field of nanomedicine include standardization and characterization of nanoparticles to ensure that nanotechnologies meet the safety\, efficacy\, and quality standards required for clinical trials; worldwide support for nanotechnology developers by offering expertise in physicochemical characterization\, immunological testing\, toxicology\, and pharmacokinetics; assisting collaborators in overcoming challenges such as toxicity\, targeting efficiency\, and scalability through comprehensive evaluation and feedback; and helping navigate the complexities of nanotechnology development\, guiding researchers towards safer and more effective nanomedicines\, facilitating the translation of promising nanotechnologies from the bench to the clinic. \nNumerous nanotechnology-based cancer therapies have emerged from NCL-supported research\, with dozens of concepts entering clinical trials\, showing promise in improving treatment outcomes and patient quality of life. \n\n\n\n\n\n\n\n\n\nFor conference-related questions \n\n\n\n\n\n\n
URL:https://www.mdtechcouncil.com/membership/events/calendar/advancing-medical-applications-of-cancer-nanotechnology/
LOCATION:The Advanced Technology Research Facility at the Frederick National Laboratory\, 8560 Progress Drive\, Frederick\, MD\, 21701
GEO:39.4387862;-77.3626059
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=The Advanced Technology Research Facility at the Frederick National Laboratory 8560 Progress Drive Frederick MD 21701;X-APPLE-RADIUS=500;X-TITLE=8560 Progress Drive:geo:-77.3626059,39.4387862
END:VEVENT
END:VCALENDAR